Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis-Reference-Cited by-同舟云学术

Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis

Published:2023-02-01 Issue:2 Volume:23 Page:207-216
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Zhang Wenjian¹,Zhou Lushan²,Di Jianzhong¹

Affiliation:

1. Department of Bariatric and Metabolic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

2. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2168647

Reference44 articles.

1. Cancer statistics, 2022

2. Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome

3. Integrated genomic analyses of ovarian carcinoma

4. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications

5. Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential drug targets for prostate cancer ： A mendelian randomization study and application for target-derived drug design;2024-09-02

2. Inhibition of the Cyclin K‐CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer;International Journal of Cancer;2023-11-02

3. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications;Advances in Medical Sciences;2023-09